SCHEMBL4983134

SCHEMBL4983134

Nc1ccc(-c2cc3cc(I)ccc3oc2=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 0.69
NCOA1 Q15788 1/20 0.66
NCOA3 Q9Y6Q9 1/20 0.66
NPC1 O15118 2/20 0.64
ADORA3 P0DMS8 1/20 0.55
MIF P14174 1/20 0.54
ACHE P22303 1/20 0.52
MAOA P21397 2/20 0.50
KDM4E B2RXH2 2/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 1/20 0.48
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 2/20 0.47
GAPDH P04406 2/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
PTGS1 P23219 1/20 0.47
ESR1 P03372 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277617 0.87 NPC1 (0.82) MAOBNCOA1NCOA3NPC1ADORA3
SCHEMBL4992695 0.82 MAOB (0.69) MAOBNCOA1NCOA3NPC1ADORA3
SCHEMBL4988885 0.81 MAOB (0.55) MAOBNPC1ADORA3MIFACHE
SCHEMBL4987026 0.81 MAOB (0.55) MAOBNPC1ADORA3MIFMAOA
SCHEMBL2202460 0.80 NCOA1 (1.00) MAOBNCOA1NCOA3NPC1MIF
SCHEMBL30096432 0.80 NCOA1 (1.00) MAOBNCOA1NCOA3NPC1MIF
SCHEMBL9637890 0.79 MAOB (0.83) MAOBNCOA1NCOA3NPC1ADORA3
SCHEMBL10144784 0.78 MAOB (0.68) MAOBNCOA1NCOA3NPC1ADORA3
SCHEMBL9079005 0.78 NPC1 (1.00) MAOBNCOA1NCOA3NPC1ADORA3
SCHEMBL8063336 0.78 NCOA1 (0.73) MAOBNCOA1NCOA3NPC1MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
EP-1815872-A1 COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS Nagasaki University (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases APP, APBA1, FABP7 MAOB 2191/4885NCOA1 1017/4885NCOA3 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.